


Amendments to the Claims


The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:


- 5 Claim 31 (currently amended): A compound of the formula:



3



4



5 or a pharmaceutically acceptable salt thereof.

Claim 32 (currently amended): A method of inhibiting ~~one or more~~ cyclin dependent ~~kinases~~ kinase1 (CDK1) or cyclin dependent kinase 2 (CDK2), comprising administering ~~a therapeutically effective amount of~~ at least one compound of claim 31 ~~to a patient in need of such inhibition~~.

10 Claim 33 (currently amended): A method of treating one or more diseases ~~associated with a kinase~~ by inhibiting CDK1 or CDK2, comprising administering ~~a therapeutically effective amount of~~ at least one compound of claim 31 ~~to a patient in need of such treatment~~.

Claim 34 (currently amended): The method of claim 33, wherein said

15 ~~kinase is~~ treatment is by inhibiting CDK2.

Claim 35 (currently amended): The method of claim 33, wherein said kinase is mitogen-activated protein kinase (MAPK/ERK) treatment is by inhibiting CDK1.

Claim 36: Cancelled.

- 5 Claim 37 (original): The method of claim 33, wherein said disease is selected from the group consisting of:

cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

- 10 leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

- 15 fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas;

melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma.

- 20 Claim 38 (currently amended): A method of treating one or more diseases associated with cyclin dependent kinase by inhibiting CDK1 or CDK2, comprising administering to a mammal ~~in need of such treatment~~

an amount of a first compound, which is a compound of claim 4 31, or a pharmaceutically acceptable salt thereof;

- 25 and

an amount of at least one second compound, said second compound being an anti-cancer agent;

wherein the amounts of the first compound and said second compound result in a therapeutic effect.

- 30 Claim 39 (original): The method of claim 38, further comprising radiation therapy.

Claim 40 (original): The method of claim 38, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan,

BEST AVAILABLE COPY

- paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide,
- 5 Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin,
- 10 Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone,
- 15 Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrozole, Letrozole, Capecitabine, Reloxafine, Droloxafine, or
- 20 Hexamethylmelamine.

Claim 41 (currently amended): A pharmaceutical composition comprising a ~~therapeutically effective amount of~~ at least one compound of claim 31 in combination with at least one pharmaceutically acceptable carrier.


- Claim 42 (original): The pharmaceutical composition of claim 39, additionally
- 25 comprising one or more anti-cancer agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa,
- 30 Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine,

BEST AVAILABLE COPY

- Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase,
- 5 Teniposide 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide,
- 10 Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrozole, Letrozole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.


Claim 43 (previously presented): A compound of claim 31 in purified form.

- 15 Claim 44 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.


Claim 45 (previously presented): A compound of the formula:



- 20 or a pharmaceutically acceptable salt thereof.


Claim 46 (previously presented): A compound of the formula:

8




or a pharmaceutically acceptable salt thereof.

Claim 47 (previously presented): A compound of the formula:




5 or a pharmaceutically acceptable salt thereof.

Claim 48 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 49 (previously presented): A compound of the formula:




10

or a pharmaceutically acceptable salt thereof.


Claim 50 (previously presented): A compound of the formula:

9




or a pharmaceutically acceptable salt thereof.

Claim 51 (previously presented): A compound of the formula:




5 or a pharmaceutically acceptable salt thereof.

Claim 52 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 53 (previously presented): A compound of the formula:




BEST AVAILABLE COPY

10

or a pharmaceutically acceptable salt thereof.

Claim 54 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

- 5 Claim 55 (currently amended): A method of inhibiting ~~one or more cyclin dependent kinases~~ CDK1 or CDK2, comprising administering ~~a therapeutically effective amount of~~ at least one compound of any of claims 44-54 to a patient.

- Claim 56 (currently amended): A method of treating one or more diseases associated with a kinase ~~by inhibiting~~ CDK1 or CDK2, comprising
10 administering ~~a therapeutically effective amount of~~ at least one compound of any of claims 44-54 to a patient.

Claim 57 (previously presented) The method of claim 56, wherein said disease is selected from the group consisting of:

- 15 cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

- 20 acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas;

melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma

- 25 pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 58 (currently amended): A method of treating one or more diseases associated with cyclin dependent kinas ~~by inhibiting~~ CDK1 or CDK2, comprising administering ~~to a mammal in need of such treatment~~

BEST AVAILABLE

11

an amount of a first compound, which is a compound of claim 44-54, or a pharmaceutically acceptable salt thereof;
and

an amount of temozolomide;

5 wherein the amounts of the first compound and said temozolomide result in a therapeutic effect.

Claim 59 (original): The method of claim 58, further comprising radiation therapy.

Claim 60 (currently amended): A pharmaceutical composition comprising (i)
10 ~~a therapeutically effective amount of~~ a compound of claim 44-54 or a pharmaceutically acceptable salt thereof, and (ii) temozolomide.

Claim 61 (currently amended): A method of inhibiting ~~one or more kinases~~ CDK1 or CDK2, comprising administering the pharmaceutical composition of claim 60.

15 Claim 62: cancelled.

Claim 63 (currently amended): A method of treating one or more diseases ~~associated with a kinase~~ by inhibiting CDK1 or CDK2, comprising administering the pharmaceutical composition of claim 60.

Claim 64 (previously presented): A method of treating a cancer, comprising
20 administering the pharmaceutical composition of claim 60.

Claim 65 (currently amended): A method of treating a cancer, comprising administering ~~a therapeutically effective amount of~~ at least one compound of claim 31.

Claim 66 (previously presented): The method of claim 65, wherein said
25 cancer is selected from the group consisting of:

cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia,
30 B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

BEST AVAILABLE COPY

astrocytoma, neuroblastoma, glioma and schwannomas;
melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma
pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's
sarcoma.

5 Claim 67 (currently amended): A method of treating a cancer, comprising
administering ~~to a mammal in need of such treatment~~

an amount of a first compound, which is a compound of claim 31, or a
pharmaceutically acceptable salt thereof;

and

10 an amount of at least one second compound, said second compound
being an anti-cancer agent;

wherein the amounts of the first compound and said second compound
result in a therapeutic effect.

15 Claim 68 (previously presented): The method of claim 67, further comprising
radiation therapy.

Claim 69 (previously presented): The method of claim 67, wherein said anti-
cancer agent is selected from the group consisting of a cytostatic agent,
cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, Irinotecan,
camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-
20 fluorouracil, methotrexate, 5FU, temozolomide, cyclophosphamide, SCH
66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to
EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil
mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman,
Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine,
25 Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine,
6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin,
leucovorin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine,
Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin,
Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide
30 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone,
Fluoxymesterone, Dromostanolone propionate, Testolactone,
Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone,
Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide,

BEST AVAILABLE COPY

13

Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrozole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or

5 Hexamethylmelamine.

Claim 70 (currently amended): A method of treating a cancer, comprising administering (i) a therapeutically effective amount of at least one compound of claim 31, and (ii) temozolomide.

BEST AVAILABLE COPY